Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial

202412 citationsJournal Articlegold Open Access

Authors

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Good health and well-being

Published in: Ophthalmology Science

Volume 5, Issue 1, pp. 100586-100586

Field-Weighted Citation Impact: 6.48